Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorIstituto Nazionale di Ricovero e Cura per Anziani

About this trial

The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.

Eligibility criteria

Qualifiers

Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis

Disqualifiers

no informed consent

inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013)

Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis

no informed consent

Trial design

Treatments tested in this trial

  • collection of blood samples

Treatment groups

400 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Istituto Nazionale di Ricovero e Cura per Anziani

Lead sponsor

Ministry of Health, Italy

Collaborator

University of Salento

Collaborator

IRCCS Multimedica

Collaborator

Azienda Ospedaliera Universitaria Policlinico "G. Martino"

Collaborator